Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2124 | Infusion of 5 mg/kg Infliximab Wiki | 0.71 |
| drug4848 | biochemical analysis Wiki | 0.71 |
| drug15 | 0.9% Sodium Chloride (Placebo) Wiki | 0.71 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
This study evaluates the effectiveness and safety of infliximab in the treatment of acute pancreatitis in adults. A third of participants will receive one single dose of infliximab via infusion, another third will receive a higher dose of infliximab via infusion and the final third of participants will receive a placebo infusion.
Description: Difference in mean serum CRP measured on (summated as AUC) in the active arms (5 mg/kg or 10 mg/kg) versus the placebo arm. CRP assays will be undertaken on blood samples centrally to ensure standardised measurement.
Measure: Difference in mean serum CRP measured on days 2, 4, 7, 14 and 28 Time: Days 2, 4, 7, 14 and 28Description: Patient will complete a Numerical Rating Scale.The scale is from 0-10 (0= no pain and 10 = worst pain possible)
Measure: Pain scores Time: First 28 DaysDescription: Recording of daily morphine equivalents by research team
Measure: Opiate requirements Time: First 28 daysDescription: Number of days nil by mouth +/- specified nutritional support
Measure: Nutritional deficit Time: First 28 daysDescription: Albumen measured via blood samples
Measure: Decline in serum albumen Time: First 28 daysDescription: Haematocrit measured via blood sample
Measure: Decline in haematocrit Time: First 28 daysDescription: Neutrophils measured in blood samples
Measure: Rise in neutrophils Time: First 28 daysDescription: Duration from admission in days
Measure: Systemic inflammatory response syndrome Time: First 28 daysDescription: Summed respiratory (0-4), cardiovascular (0-4) and renal (0-4) SOFA scores on each of the first 28 days after hospital admission
Measure: Sequential organ failure assessment (SOFA) score Time: First 28 daysDescription: Contrast-enhanced CT scan assessed by a central panel
Measure: Local pancreatic injury Time: Day 14 onlyDescription: RAC severity classification (mild, moderate or severe)
Measure: Revised Atlanta Classification (RAC) Time: 90 days after admissionDescription: Infective complications reported
Measure: Infective complications Time: First 90 daysDescription: Length of time patient remains within hospital as an inpatient
Measure: Length of hospital stay Time: Up to 90 daysDescription: Patient death
Measure: Mortality Time: Within the first 90 daysDescription: EuroQol EQ-5D-5L
Measure: Patient reported outcome Time: Day 4, Day 14, Day 28 and Day 90Description: Adverse events relating to infliximab including infusion reactions and delayed serum sickness reactions
Measure: Potential safety signals Time: Up to 90 daysDescription: Blood sample analysis to determine the concentration of anti-infliximab antibodies
Measure: Anti-infliximab antibody concentration Time: Day 28Description: QALYs using data from the EQ-5D-5L questionnaire
Measure: Incremental cost per quality adjusted life years (QALY) gained by trial treatment Time: Days 4, 14 , 28 and 90Although COVID-19 disease due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract, heart and coagulation system, symptoms of gastrointestinal system involvement such as abdominal pain, nausea, vomiting and diarrhea are also common. In this study, it was aimed retrospective analysis of clinical and laboratory data of patients who developed pancreatic injury in the course of COVID 19 disease.
Description: To evaluate the frequency of presence of fever in patients with and without pancreatic injury
Measure: to compare presence of fever in patients with and without pancreatic injury Time: 3 monthDescription: To evaluate the frequency of presence of dyspnea in patients with and without pancreatic injury
Measure: to compare presence of dyspnea in patients with and without pancreatic injury Time: 3 monthDescription: CRP levels will be compared in patients with and without pancreatic injury
Measure: To compare cRP levels in patients with and without pancreatic injury Time: 3 monthDescription: D-Dimer levels will be compared in patients with and without pancreatic injury
Measure: To compare d-dimer levels in patients with and without pancreatic injury Time: 3 monthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports